SCHEMBL10007263

SCHEMBL10007263

Cn1c(=O)n(C(=O)N2CCCC2)c2cnc(-c3ccccc3)nc21

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.47
TSPO P30536 1/20 0.44
CNR1 P21554 1/20 0.40
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GRIN2B Q13224 2/20 0.39
GRIN1 Q05586 1/20 0.39
HTT P42858 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
LIPE Q05469 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10006720 0.99 HPGD (0.49) HPGDTSPOCNR1TSHRMAPK1
SCHEMBL10007507 0.98 HPGD (0.45) HPGDTSPOCNR1TSHRMAPK1
SCHEMBL10007101 0.91 TSPO (0.48) HPGDTSPOCNR1TSHRMAPK1
SCHEMBL10006683 0.90 HPGD (0.43) HPGDTSPOGRIN2BGRIN1
SCHEMBL10006632 0.90 CNR1 (0.41) HPGDCNR1TSHRNPC1TP53
SCHEMBL10006937 0.89 HPGD (0.44) HPGDTSHRGRIN2BGRIN1ALDH1A1
SCHEMBL10007254 0.89 L3MBTL1 (0.44) TSPOTSHRMAPK1TP53SMN1; SMN2
SCHEMBL10006571 0.89 TSPO (0.47) HPGDTSPOCNR1TSHRMAPK1
SCHEMBL10006699 0.89 HDAC1 (0.47) HPGDNPC1RAB9ASMN1; SMN2GRIN2B
SCHEMBL10267724 0.89 TSPO (0.48) HPGDTSPOCNR1TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2476682-B1 8-OXODIHYDROPURINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2017-04-26 EP disclosed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 US disclosed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 US disclosed
EP-2476682-A1 8-OXODIHYDROPURINE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-07-18 EP disclosed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 US disclosed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE FAAH, FAAH2, TPMT HPGD 170/4885TSPO 1233/4885CNR1 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.